This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Patterson (PDCO) Rewards Shareholders with 8% Dividend Hike
by Zacks Equity Research
Patterson Companies Inc. (PDCO) recently hiked its quarterly dividend by 8% to 26 cents per share from 24 cents.
Air Methods (AIRM) Set to be Acquired for $2.5 Billion
by Zacks Equity Research
Air Methods Corporation (AIRM) announced that it is set to be acquired by New York-based private equity firm American Securities LLC for $2.5 billion.
Medtronic's New Reveal LINQ ICM Gets FDA 510(k) Clearance
by Zacks Equity Research
Medical device major, Medtronic plc (MDT) recently received the U.S. FDA 510(k) clearance for its Reveal LINQ Insertable Cardiac Monitor (ICM) with TruRhythm Detection.
AngioDynamics Microwave Tissue Ablation System Now CE Marked
by Zacks Equity Research
AngioDynamics Inc. (ANGO), a leading provider of minimally invasive medical devices, recently announced the receipt of CE mark for Solero Microwave Tissue Ablation (MTA) System.
Stryker Launches MAKO Robotic-Arm for Knee Anthroplasty
by Zacks Equity Research
Stryker Corporation (SYK) recently announced the commercial launch of a robotic-arm assisted total knee arthroplasty application based on its flagship MAKO System.
IDEXX (IDXX) Poised on Strong Fundamentals, Innovations
by Zacks Equity Research
On Mar 14, we issued an updated research report on IDEXX Laboratories, Inc. (IDXX).
Ensign Group Signs Lease Agreement with Mainstreet Health
by Zacks Equity Research
The Ensign Group, Inc. (ENSG) recently signed definitive agreements to simultaneously sell and lease two skilled nursing facilities and one assisted living community to Mainstreet Health Investments Inc.
Is it Wise to Hold Universal Health (UHS) in Your Portfolio?
by Zacks Equity Research
Headquartered in King of Prussia, PA, Universal Health Services Inc. (UHS) stock has gained 12.8% year to date, significantly higher than the increase of 7.6% witnessed by the Zacks categorized medical sector.
Zacks.com featured highlights: Children's Place, Broadcom, Stoneridge, Inogen and Customers Bancorp
by Zacks Equity Research
Zacks.com featured highlights: Children's Place, Broadcom, Stoneridge, Inogen and Customers Bancorp
5 Top-Ranked Stocks to Tap Earnings Beat Potential
by Zacks Equity Research
Forget earnings growth, bet on these top-ranked stocks to cash in on earnings beat.
Neovasc (NVCN) Catches Eye: Stock Adds 27.1% in Session
by Zacks Equity Research
Neovasc Inc. (NVCN) moved big last session, as its shares jumped a little over 27% on the day.
Corindus Vascular Robotics (CVRS) Jumps: Stock Gains 19.5%
by Zacks Equity Research
Corindus Vascular Robotics, Inc. (CVRS) move big last session, as its shares rose over 19% on the day.
Adopt Driehaus Strategy and Invest in These 5 Stocks
by Zacks Equity Research
Investors with a high risk appetite might use Driehaus Strategy that target healthy returns through investment in momentum stocks.
Tenet Healthcare (THC) Signs Multi-Year Deal with BCBSTX
by Zacks Equity Research
Tenet Healthcare Corporation (THC) recently inked a deal with Blue Cross and Blue Shield of Texas ("BCBSTX").
Medtronic's Pacemaker Business Wins CMS Coverage Approval
by Zacks Equity Research
Medtronic plc (MDT) recently won the U.S. CMS coverage approval for its Micra Transcatheter Pacing System (TPS).
Myriad Genetics (MYGN) Launches EndoPredict Test in the US
by Zacks Equity Research
Myriad Genetics, Inc. (MYGN), a leading name in the molecular diagnostics space, recently launched the EndoPredict test in the U.S. for patients with ER+ HER2 -- early-stage breast cancer.
Cantel Medical (CMD) Q2 Earnings & Sales Grow Year Over Year
by Zacks Equity Research
Cantel Medical Corp. (CMD) reported adjusted earnings of 52 cents per share in the second quarter of fiscal 2017.
Medtronic Initiates BTK Study on DCB for PAD Cure in Europe
by Zacks Equity Research
Medtronic plc (MDT) recently initiated the IN.PACT below-the-knee (BTK) study to evaluate the effectiveness of a drug-coated balloon for treatment of peripheral arterial disease (PAD).
Humana's Subsidiaries Receive Rating Action from A.M. Best
by Zacks Equity Research
Humana Inc. (HUM) recently received rating action from A.M. Best. The rating giant has removed from under review, with positive implications, the majority of insurance subsidiaries of the company.
The Zacks Analyst Blog Highlights: Inogen, OraSure Technologies, Lannett and Cardiovascular Systems
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Inogen, OraSure Technologies, Lannett and Cardiovascular Systems
UnitedHealth's Senior Unsecured Notes Rated by A.M Best
by Zacks Equity Research
UnitedHealth Group, Inc.'s (UNH) senior unsecured notes recently received rating action from A.M Best.
Earnings Estimates Moving Higher for Inogen (INGN): Time to Buy?
by Zacks Equity Research
Inogen (INGN) has seen positive earnings estimate revisions for the current quarter and year, in addition to decent short-term price momentum.
VWR Corporation (VWR): Q4 Lacks Shine, Currency Woes Remain
by Zacks Equity Research
On Mar 9, we issued an updated research report on Radnor, PA-based VWR Corporation (VWR) -- a global provider of products, services and solutions to laboratory and production facilities.
4 Big Winners of Trump's Healthcare Plan
by Swarup Gupta
The new healthcare legislation has its own sets of winners and losers.
3 Reasons Why Inogen (INGN) is a Great Momentum Stock
by Zacks Equity Research
Let's focus on Inogen, Inc. (INGN) as this momentum stock is looking especially impressive right now.